BALCOLTRA (levonorgestrel and ethinyl estradiol) by Xeltis is ovulation. First approved in 2018.
Drug data last refreshed 4h ago · AI intelligence enriched 6h ago
BALCOLTRA is an oral contraceptive containing levonorgestrel and ethinyl estradiol, indicated for prevention of pregnancy in women of reproductive age. It works primarily by inhibiting ovulation, with secondary mechanisms including cervical mucus thickening and endometrial changes that reduce implantation likelihood.
Product approaching loss of exclusivity with minimal current spending signals small commercial team and declining growth trajectory.
ovulation. Other possible mechanisms may include cervical mucus changes that inhibit sperm penetration and endometrial changes that reduce the likelihood of implantation.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Postmarketing Open-Label Study to Assess Residual Levonorgestrel (LNG) and Ethinyl Estradiol (EE) Content of TWIRLA® (Levonorgestrel and Ethinyl Estradiol) Transdermal System
Study to Evaluate the Pharmacokinetics of an Oral Contraceptive Containing Levonorgestrel and Ethinyl Estradiol When Co-administered With GSK1265744 in Healthy Adult Female Subjects
Investigation Of The Effect Of Steady State Filibuvir On The Pharmacokinetics Of Oral Contraceptives (Levonorgestrel And Ethinyl Estradiol)
AG200-15 Transdermal Contraceptive Delivery System (TCDS) of Levonorgestrel and Ethinyl Estradiol
Study Evaluating Combination of Levonorgestrel and Ethinyl Estradiol in Pre-Menstrual Dysphoric Disorder
Worked on BALCOLTRA at Xeltis? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moPatent cliff in less than a year — expect lifecycle management and generic defense hiring
BALCOLTRA offers limited career growth potential given its approaching loss of exclusivity and minimal current job openings. Working on this product would be suitable for professionals seeking a lower-stakes, maintenance-focused role rather than a high-growth launch or peak-sales assignment.